WKF | CV death or HHF | ||||
Event (n=677), n (%) | No event (n=117 985), n (%) | Crude HR (95% CI) | Adjusted HR (95% CI)* | P value* | |
>30% eGFR drop (n=18 585) | 242 (35.7) | 18 343 (15.6) | 2.23 (1.88 to 2.64) | 1.97 (1.66 to 2.34) | <0.001 |
>40% eGFR drop (n=8211) | 152 (22.5) | 8059 (6.8) | 2.75 (2.25 to 3.36) | 2.51 (2.06 to 3.07) | <0.001 |
>50% eGFR drop (n=3246) | 83 (12.3) | 3163 (2.7) | 3.21 (2.48 to 4.16) | 3.03 (2.33 to 3.92) | <0.001 |
WKF | CV death | ||||
Event (n=331), n (%) | No event (n=118 331), n (%) | Crude HR (95% CI) | Adjusted HR (95% CI)* | P value* | |
>30% eGFR drop (n=18 585) | 96 (29.0) | 18 489 (15.6) | 2.09 (1.62 to 2.70) | 1.89 (1.47 to 2.45) | <0.001 |
>40% eGFR drop (n=8211) | 56 (16.9) | 8155 (6.9) | 2.57 (1.87 to 3.51) | 2.41 (1.77 to 3.29) | <0.001 |
>50% eGFR drop (n=3246) | 31 (9.4) | 3215 (2.7) | 3.35 (2.23 to 5.03) | 3.29 (2.19 to 4.92) | <0.001 |
HHF (n=444) | 98 (29.6) | 346 (3.5)† | 8.58 (6.67 to 11.0) | 5.17 (3.91 to 6.83) | <0.001 |
No interaction of WKF by baseline eGFR was observed; interaction p>0.1 in all models.
*Model adjusted for age (≤65 years vs >65 years), sex (female vs male), history of cardiovascular disease including hospitalization for heart failure (yes vs no), urinary albumin to creatinine ratio (≤30 mg/g vs >30 mg/g), waist circumference (≤88 cm for women and ≤102 cm for men vs >88 cm for women and >102 cm for men), glycated hemoglobin (≤8% vs >8%), and randomized treatment (intensive vs standard glucose-lowering treatment).
†Only the first HHF episode registered in the data set.
CV, cardiovascular; eGFR, estimated glomerular filtration rate; HHF, hospitalization for heart failure; WKF, worsening kidney function.